BRIDGEBIO ANNOUNCES FIRST PARTICIPANT DOSED IN ASCEND-ATTR, A PHASE 3B/4 STUDY EVALUATING THE LONG-TERM EFFECTS OF ACORAMIDIS ON DISEASE REGRESSION IN ATTR-CM

Reuters · 3d ago

Please log in to view news